Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.48 BRL | 0.00% | +2.19% | +15.08% |
05-09 | ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive... | |
05-09 | Redburn Atlantic Adjusts Price Target on Amgen to $180 From $170 | MT |
Business Summary
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Number of employees: 26,700
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Human Therapeutics
95.5
%
| 24,801 | 94.2 % | 26,910 | 95.5 % | +8.50% |
Other
4.5
%
| 1,522 | 5.8 % | 1,280 | 4.5 % | -15.90% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
70.3
%
| 18,595 | 70.6 % | 19,806 | 70.3 % | +6.51% |
Rest of World
29.6
%
| 7,655 | 29.1 % | 8,337 | 29.6 % | +8.91% |
Canada
0.2
%
| 73 | 0.3 % | 47 | 0.2 % | -35.62% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 31/05/06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 22/10/19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 12-17 |
Chief Tech/Sci/R&D Officer | 53 | - | |
Esteban Santos
COO | Chief Operating Officer | 56 | 31/12/06 |
Nancy Grygiel
CMP | Compliance Officer | 56 | 31/12/14 |
Mike Zahigian
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/00 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/12/04 |
Darryl Sleep
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/18 |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 55 | 31/05/23 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 02/02/17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 13/10/16 |
Robert Williams
BRD | Director/Board Member | 75 | 16/10/14 |
Robert Eckert
BRD | Director/Board Member | 69 | 31/12/02 |
Ronald Sugar
BRD | Director/Board Member | 75 | 21/07/10 |
Robert Bradway
CEO | Chief Executive Officer | 61 | 31/05/06 |
Wanda Austin
BRD | Director/Board Member | 69 | 23/10/17 |
Tyler Jacks
BRD | Director/Board Member | 63 | 31/12/11 |
Omar Ishrak
BRD | Director/Board Member | 68 | 29/07/21 |
Greg Garland
BRD | Director/Board Member | 66 | 15/10/13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 536,434,692 | 535,106,546 ( 99.75 %) | 0 | 99.75 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
BEIGENE, LTD. 19.82% | 246,269,426 | 19.82% | 2,992,444,422 $ |
4,910,000 | 5.50% | 116,121,500 $ | |
VIGIL NEUROSCIENCE, INC. 8.69% | 3,206,281 | 8.69% | 10,933,418 $ |
100,993 | 0.67% | 2,965,154 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the private company is Gabor Sztaniszlav. |
Pharmaceuticals: Major
|
Amgen Technology Ltd.
Amgen Technology Ltd. BiotechnologyHealth Technology Part of Amgen, Inc., Amgen Technology Ltd. develops, manufactures and markets human therapeutic products based on cellular biology. The private company is located in Bermuda. |
Biotechnology
|
Amgen Manufacturing Ltd. (Bermuda)
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
-2.71% | 159B |
- Stock Market
- Equities
- AMGN Stock
- AMGN34 Stock
- Company Amgen Inc.